@article{570473158deb49968be3a3aead88811d,
title = "Influence of Gut Microbiota on Progression to Tuberculosis Generated by High Fat Diet-Induced Obesity in C3HeB/FeJ Mice",
abstract = "The administration of a high fat content diet is an accelerating factor for metabolic syndrome, impaired glucose tolerance, and early type 2 diabetes. The present study aims to assess the impact of a high fat diet on tuberculosis progression and microbiota composition in an experimental animal model using a C3HeB/FeJ mouse strain submitted to single or multiple consecutive aerosol infections. These models allowed us to study the protection induced by Bacillus Calmette-Gu{\'e}rin vaccination as well as by the natural immunity induced by chemotherapy after a low dose Mycobacterium tuberculosis infection. Our results show that a high fat diet is able to trigger a pro-inflammatory response, which results in a faster progression toward active tuberculosis and an impaired protective effect of BCG vaccination, which is not the case for natural immunity. This may be related to dysbiosis and a reduction in the Firmicutes/Bacteroidetes ratio in the gut microbiota caused by a decrease in the abundance of the Porphyromonadaceae family and, in particular, the Barnesiella genus. It should also be noted that a high fat diet is also related to an increase in the genera Alistipes, Parasuterella, Mucispirillum, and Akkermansia, which have previously been related to dysbiotic processes. As diabetes mellitus type 2 is a risk factor for developing tuberculosis, these findings may prove useful in the search for new prophylactic strategies for this population subset.",
keywords = "BCG, C3HeB/FeJ, comorbidity, gut microbiota, high fat diet, mice, obesity, tuberculosis",
author = "Lilibeth Arias and Goig, {Galo Adri{\'a}n} and Paula Cardona and Manuela Torres-Puente and Jorge D{\'i}az and Yaiza Rosales and Eric Garcia and Gustavo Tapia and I{\~n}aki Comas and Cristina Vilaplana and Cardona, {Pere Joan}",
note = "Funding Information: This work was supported by the European Commission Horizon 2020 research and innovation program under grant agreement TBVAC2020 No. 643381, European Research Council research grant 638553-TB-ACCELERATE and Ministerio de Econom{\'i}a y Competitividad (Spanish government) research grant SAF2017-92345-EXP (to IC). CV has a project Servet II contract funded by the Instituto de Salud Carlos III (ISCIII, CPII 18/00031). LA received an Improvement and Mobility Program grant from the Centro de Investigaci{\'o}n Biom{\'e}dica en Red de Enfermedades Respiratorias (CIBERES). GG contract was funded by Ministerio de Economia y Competitividad (Spanish Government) (BES-2014-071066). PC contract was funded by the Instituto de Salud Carlos III (IFI14/00015). The Experimental Tuberculosis Unit is accredited by the Catalan Agency for Management of University and Research Grants with code 2017 SGR500 and the IGTP is a member of the CERCA network of institutes. The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2019 Arias, Goig, Cardona, Torres-Puente, D{\'i}az, Rosales, Garcia, Tapia, Comas, Vilaplana and Cardona. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = oct,
day = "18",
doi = "10.3389/fimmu.2019.02464",
language = "Ingl{\'e}s estadounidense",
volume = "10",
journal = "Frontiers in immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
}